The maker of a drug for Lou Gehrig's disease that recently failed in a large study said Thursday that it will withdraw it from the market, acknowledging that it does not help patients with the deadly neurological disease. Amylyx Pharmaceuticals announced that it would voluntarily stop sales and marketing of the drug in the United States and Canada and that new patients would no longer be able to receive the treatment. "While this is a difficult time for the ALS community, we have worked with the stakeholders who will be affected to achieve this path forward based on our unwavering commitment to people with ALS," said Koon in a statement.